For decades the entire hair-loss field has rested on just two FDA-approved drugs, a DHT-suppressing hormonal agent and a vasodilator discovered by accident, with almost everything newer being a reformulation or an off-label repurposing. What does the persistence of this narrow paradigm reveal about how poorly we still understand follicle biology, and is the DHT-and-androgen-receptor model a complete account of pattern baldness or a local optimum that has quietly capped how ambitious the field allows itself to be?
The persistence of the two-drug paradigm, centered on finasteride and minoxidil, represents a "local optimum" in hair-loss science rather than a comprehensive understanding of follicle biology Verified Answer #1, Verified Answer #2. While these treatments target accessible intervention points—specifically androgen suppression and vascular support—they do not reflect a mature mechanistic map of follicle state control Verified Answer #2, Verified Answer #3. This stagnation is driven by the commercial viability of modest maintenance therapies and a high regulatory threshold that makes it difficult and expensive for novel, multi-pathway therapeutics to outperform established drugs in clinical trials Verified Answer #1, Verified Answer #4.
The dihydrotestosterone (DHT) and androgen-receptor (AR) model is considered an indispensable and necessary upstream trigger for pattern baldness, but it is an incomplete systems-biology account Verified Answer #1, Verified Answer #2. While the model correctly identifies how DHT triggers follicular miniaturization in genetically susceptible individuals, it fails to explain complex phenomena such as regional patterning, progressive irreversibility, and regenerative failure Verified Answer #1, Verified Answer #3. For instance, the classic endocrine model struggles to explain why systemic DHT causes hair loss at the vertex and temples while sparing the occipital region Verified Answer #1.
Modern research suggests that androgenetic alopecia is a complex, polygenic disorder involving multiple interacting molecular mechanisms beyond a single hormonal pathway Verified Answer #4, Verified Answer #3. These layers include Wnt/β-catenin signaling dysfunction, extracellular matrix remodeling, micro-inflammation, fibrosis, and stem cell exhaustion Verified Answer #4, Verified Answer #3. The dominance of the DHT/AR paradigm has effectively capped the field's ambition, as the existing "good enough" treatments create a high barrier to entry for more ambitious approaches like gene regulation or stem cell-based therapies Verified Answer #2, Verified Answer #4.